Arrowhead Research | ARWR - Assets


Arrowhead Research reported $2.11B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026
Xencor USD 724.96M 11.89M Jun/2026